Combined patients from EASIX unmodified and CD34+-selected datasets
| Patient characteristics . | Total . | Cohort 1 (Unmodified) . | Cohort 2 (CD34) . |
|---|---|---|---|
| Sample size, n (%) | 509 (100) | 149 (29) | 360 (71) |
| Female, n (%) | 209 (41) | 45 (30) | 164 (46) |
| Median age at transplant, y (range) | 55.6 (19.6-78.7) | 55.0 (23.6-78.7) | 55.8 (19.6-73.3) |
| Disease group, n (%) | |||
| Acute leukemia | 222 (44) | 4 (3) | 218 (61) |
| Chronic leukemia | 41 (8) | 22 (15) | 19 (5) |
| MDS | 100 (20) | 0 | 100 (28) |
| HL | 20 (4) | 20 (13) | 0 |
| NHL | 108 (21) | 103 (69) | 5 (1) |
| MPD | 18 (4) | 0 | 18 (5) |
| HCT-CI score, n (%) | |||
| 0 | 121 (24) | 48 (32) | 73 (20) |
| 1-2 | 165 (32) | 40 (27) | 125 (35) |
| ≥3 | 223 (44) | 61 (41) | 162 (45) |
| Donor type, n (%) | |||
| Matched related | 189 (37) | 61 (41) | 128 (36) |
| Mismatched related | 1 (0.2) | 0 | 1 (0.3) |
| Matched unrelated | 246 (49) | 74 (50) | 172 (48) |
| Mismatched unrelated | 72 (14) | 14 (9) | 58 (16) |
| Conditioning intensity, n (%) | |||
| Ablative | 357 (70) | 0 | 357 (99) |
| Reduced | 41 (8) | 38 (26) | 3 (1) |
| Nonmyeloablative | 111 (22) | 111 (74) | 0 |
| Conditioning regimen, n (%) | |||
| Myeloablative, chemotherapy-based | 244 (68) | ||
| Myeloablative, high-dose TBI-based | 116 (32) | ||
| Melphalan/fludarabine | 27 (18) | ||
| Low-dose TBI | 117 (79) | ||
| Other | 5 (3) | ||
| Graft source, n (%) | |||
| Bone marrow | 2 (0.4) | 2 (1) | 0 |
| Peripheral blood stem cell | 507 (99.6) | 147 (99) | 360 (100) |
| Patient characteristics . | Total . | Cohort 1 (Unmodified) . | Cohort 2 (CD34) . |
|---|---|---|---|
| Sample size, n (%) | 509 (100) | 149 (29) | 360 (71) |
| Female, n (%) | 209 (41) | 45 (30) | 164 (46) |
| Median age at transplant, y (range) | 55.6 (19.6-78.7) | 55.0 (23.6-78.7) | 55.8 (19.6-73.3) |
| Disease group, n (%) | |||
| Acute leukemia | 222 (44) | 4 (3) | 218 (61) |
| Chronic leukemia | 41 (8) | 22 (15) | 19 (5) |
| MDS | 100 (20) | 0 | 100 (28) |
| HL | 20 (4) | 20 (13) | 0 |
| NHL | 108 (21) | 103 (69) | 5 (1) |
| MPD | 18 (4) | 0 | 18 (5) |
| HCT-CI score, n (%) | |||
| 0 | 121 (24) | 48 (32) | 73 (20) |
| 1-2 | 165 (32) | 40 (27) | 125 (35) |
| ≥3 | 223 (44) | 61 (41) | 162 (45) |
| Donor type, n (%) | |||
| Matched related | 189 (37) | 61 (41) | 128 (36) |
| Mismatched related | 1 (0.2) | 0 | 1 (0.3) |
| Matched unrelated | 246 (49) | 74 (50) | 172 (48) |
| Mismatched unrelated | 72 (14) | 14 (9) | 58 (16) |
| Conditioning intensity, n (%) | |||
| Ablative | 357 (70) | 0 | 357 (99) |
| Reduced | 41 (8) | 38 (26) | 3 (1) |
| Nonmyeloablative | 111 (22) | 111 (74) | 0 |
| Conditioning regimen, n (%) | |||
| Myeloablative, chemotherapy-based | 244 (68) | ||
| Myeloablative, high-dose TBI-based | 116 (32) | ||
| Melphalan/fludarabine | 27 (18) | ||
| Low-dose TBI | 117 (79) | ||
| Other | 5 (3) | ||
| Graft source, n (%) | |||
| Bone marrow | 2 (0.4) | 2 (1) | 0 |
| Peripheral blood stem cell | 507 (99.6) | 147 (99) | 360 (100) |
Percentages may add up to greater than 100 due to rounding.
HCT-CI, hematopoietic cell transplantation-specific comorbidity index; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma; TBI, total body irradiation.